No Data
Jia Biyou: Summary of the 2024 Annual Report of Jia Biyou Biotechnology (Wuhan) Co., Ltd.
Jia Biyou: Jia Biyou Biotechnology (Wuhan) Co., Ltd. 2024 Annual Report
Cabio Biotech(Wuhan) Co., Ltd. 2024 Annual Report
Cabio Biotech (Wuhan) Co., Ltd. Summary of the Annual Report for 2024.
Cabio Biotech(Wuhan) (688089.SH): In 2024, net income is expected to grow by 35.94% year-on-year, and a dividend of 2 yuan will be distributed for every 10 shares.
Gelonghui reported on March 27 that Cabio Biotech (Wuhan) (688089.SH) announced its annual report for 2024, with revenue of 0.556 billion yuan, a year-on-year increase of 25.19%, net income of 0.124 billion yuan, a year-on-year increase of 35.94%, and a non-deductive net income of 99.9899 million yuan, a year-on-year increase of 60.11%. A cash dividend of 2 yuan per 10 shares will be distributed to all shareholders.
Analysis of the Cabio Biotech(Wuhan) acquisition case: How does the symbol Ouyi Bio support a valuation of 1.3 billion with earnings of 0.043 billion over three quarters?|Focus
① Jinzheng Assessment stated that future expected profitability is at the core of a company's value, and it is estimated that Ouyi Biological's revenue will reach 0.48 billion yuan, 0.558 billion yuan, and 0.637 billion yuan from 2025 to 2027 respectively; ② "Valuation inclusivity does not mean accepting overvaluations, but rather accepting valuations that clearly analyze the business logic and valuation logic of mergers and acquisitions," said Lin Li, president of Jinzheng Assessment.